TP53 Alterations Emerge as Critical Adverse Prognostic Factor in Pediatric and Young Adult Patients Treated with CD19-CAR T-Cell Therapy for Relapsed/Refractory B-ALL
Posted inHematology-Oncology news Pediatrics

TP53 Alterations Emerge as Critical Adverse Prognostic Factor in Pediatric and Young Adult Patients Treated with CD19-CAR T-Cell Therapy for Relapsed/Refractory B-ALL

A single-center retrospective study of 69 pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia reveals that TP53 alterations significantly compromise outcomes following tisagenlecleucel therapy. Patients harboring TP53 mutations or deletions demonstrated markedly lower remission rates and substantially worse event-free and overall survival compared to TP53 wild-type counterparts.
Does Stage Explain It All? The BENCHISTA Study Reveals Persistent Survival Gaps in Pediatric Oncology
Posted innews Oncology Pediatrics

Does Stage Explain It All? The BENCHISTA Study Reveals Persistent Survival Gaps in Pediatric Oncology

The BENCHISTA study analyzes survival disparities in six childhood solid tumors across 27 countries, revealing that while stage at diagnosis influences outcomes, significant international survival variations persist for Ewing sarcoma and medulloblastoma even after stage adjustment, suggesting the need for broader healthcare system improvements.